Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide + Insulin in Japanese T2D
NCT02750410Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2016
- Primary completion
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dulaglutide biosimilar 14028 injection in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Hemoglobin A1c at 16 weeks. Started Aug 2016; status: completed.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02750410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02750410.